ICAAC 44th Washington 2004

44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington

Tipranavir in treatment experienced patients: results from RESIST-1

Reverset: first data in patients with nucleoside resistance

Poor response with tenofovir and ddI backbone causes early study termination

Paradoxical CD4 response with tenofovir and ddI backbone

Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy

Limited stability of lopinavir/r (Kaletra) above 25°C

Atorvastatin requires dose reduction with tipranavir/r

Once-daily T-20 is less effective than twice daily: lower potency is related to C trough

Further genetic link to efavirenz absorption

Long-term response to FTC in children is similar to adults

Side effects update: hypersensitivity, heart, bones